Available company data, source links and archived checks for Alkem Laboratories Limited. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.
Quarter ended 2026-06-30 · consolidated · Company filing
| Quarter | Revenue / income | YoY | Profit | YoY | Net margin | Source |
|---|---|---|---|---|---|---|
| Jun 2026 | Revenue: ₹3,740 cr | +10.9% | Net profit: ₹521 cr | -22.0% | 13.9% | Company filing source |
| Mar 2026 | Revenue: ₹3,603 cr | +14.6% | Net profit: ₹251 cr | -22.1% | 7.0% | Company filing source |
| Dec 2025 | Revenue: ₹3,737 cr | — | Net profit: ₹653 cr | — | 17.5% | Company filing source |
| Sep 2025 | Revenue: ₹4,001 cr | — | Net profit: ₹779 cr | — | 19.5% | Company filing source |
| Jun 2025 | Revenue: ₹3,371 cr | +11.2% | Net profit: ₹668 cr | +21.4% | 19.8% | Company filing source |
| Mar 2025 | Revenue: ₹3,144 cr | — | Net profit: ₹322 cr | — | 10.3% | Company filing source |
YoY means change from the same quarter a year earlier. — means no comparable figure is available. Older entries with incomplete source details have not been revalidated under the current checks.
ALKEM
Inspiring Healthier Lives
15 th September, 2026
To,
Column boundaries are incomplete. Use the source document to interpret these figures.
| The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 | National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. Scrip Symbol: ALKEM | |---------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
Sub: Disclosure under Regulation 30(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('SEBI LODR Regulations'): Appointment of Senior Management Personnel
Dear Sir(s)/Madam,
Pursuant to Regulation 30 of the SEBI LODR Regulations, we wish to inform you that Dr. Shubhadeep Sinha has been appointed at senior management position in the Company effective from 15 th September, 2026.
Further, the details as required in terms of Regulation 30 read with Schedule III, Part A of the SEBI LODR Regulations and SEBI Master Circular bearing HO/49/14/14(7)2025CFDPOD2/I/3762/2026 dated January 30, 2026 is provided in Annexure I to this letter.
The above information is also available on the website of the Company www.alkemlabs.com.
ALKEM: consolidated net profit changed by -22.0% in the quarter ending 30 June 2026, compared with the quarter ending 2025-06-30.
ALKEM: consolidated net profit for the quarter ending 30 June 2026 was ₹520.98 crore.
ALKEM: consolidated revenue changed by 10.9% in the quarter ending 30 June 2026, compared with the quarter ending 2025-06-30.
ALKEM: consolidated revenue for the quarter ending 30 June 2026 was ₹3,740.15 crore.
Keep its available filings, dated fact checks and disclosure alerts together. Your saved country sets your market and its research schedule.
Start free — first week on us →Company data and archived claim checks are shown with available sources. Check the source and date before relying on a figure. This is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI. Terms, disclosures and grievances